Literature DB >> 22350668

Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas.

Hideo Arai1, Hayato Ikota, Ken-ichi Sugawara, Sumihito Nobusawa, Junko Hirato, Yoichi Nakazato.   

Abstract

One of the type VI intermediate filament proteins, nestin, is expressed in neuroepithelial stem cells during neural embryogenesis. Nestin is also expressed in a variety of neoplasms. Its expression in brain tumors has not been thoroughly studied. The objectives of this study were to survey nestin expression in different types of brain tumor, and to evaluate nestin as a marker for diagnosis and prognosis. We used tissue microarrays of 257 brain tumors for an immunohistochemical overview of nestin expression: nestin was frequently expressed in gliomas and schwannomas. Most of the gliomas that expressed high levels of nestin were high-grade gliomas (anaplastic astrocytomas, anaplastic oligodendrogliomas, anaplastic oligoastrocytomas, and glioblastomas). We then focused on high-grade gliomas and performed immunohistochemistry again, using whole-mount slides. As a result, we found (1) significantly different nestin expression between glioblastomas and other high-grade gliomas, and (2) worse overall survival for high-grade gliomas with high nestin expression. Our results suggest that: (1) nestin is a useful marker for diagnosis of high-grade gliomas, (2) nestin is helpful in diagnosis of schwannomas, and (3) nestin expression is related to poor prognosis in high-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350668     DOI: 10.1007/s10014-012-0081-5

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  26 in total

1.  Malignant clinical features of anaplastic gliomas without IDH mutation.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Takuhiro Shoji; Masayuki Kanamori; Ryuta Saito; Tomoo Inoue; Tomohiro Kawaguchi; Yoji Yamashita; Takashi Watanabe; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2014-06-23       Impact factor: 12.300

2.  Clinical value of CD133 and nestin in patients with glioma: a population-based study.

Authors:  Rikke H Dahlrot; Steinbjørn Hansen; Stine S Jensen; Henrik D Schrøder; Jacob Hjelmborg; Bjarne W Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 3.  What is the clinical value of cancer stem cell markers in gliomas?

Authors:  Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

4.  Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas.

Authors:  Leomar Y Ballester; Zengfeng Wang; Shaefali Shandilya; Markku Miettinen; Peter C Burger; Charles G Eberhart; Fausto J Rodriguez; Eric Raabe; Javad Nazarian; Katherine Warren; Martha M Quezado
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

Review 5.  Restore the brake on tumor progression.

Authors:  Renata E Gordon; Li Zhang; Zeng-Jie Yang
Journal:  Biochem Pharmacol       Date:  2017-04-05       Impact factor: 5.858

6.  Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis.

Authors:  Donglai Lv; Lin Lu; Zongtao Hu; Zhenle Fei; Meiqin Liu; Lei Wei; Jun Xu
Journal:  Mol Neurobiol       Date:  2016-01-14       Impact factor: 5.590

Review 7.  Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.

Authors:  Bin Wu; Caixing Sun; Fang Feng; Minghua Ge; Liang Xia
Journal:  J Exp Clin Cancer Res       Date:  2015-05-14

8.  Tuberous Sclerosis (tsc2+/-) Model Eker Rats Reveals Extensive Neuronal Loss with Microglial Invasion and Vascular Remodeling Related to Brain Neoplasia.

Authors:  Viera Kútna; Libor Uttl; Robert Waltereit; Zdenka Krištofiková; Daniel Kaping; Tomáš Petrásek; Cyril Hoschl; Saak V Ovsepian
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

Review 9.  The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.

Authors:  Joshua D Bernstock; Samantha E Hoffman; Jason A Chen; Saksham Gupta; Ari D Kappel; Timothy R Smith; E Antonio Chiocca
Journal:  Viruses       Date:  2021-06-17       Impact factor: 5.048

10.  High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.

Authors:  Tianshen Hu; Vamsidhara Vemireddy; Kimmo J Hatanpaa; Chan Foong; Jack M Raisanen; Dwight Oliver; Matthew C Hiemenz; Dennis K Burns; Charles L White; L Anthony Whitworth; Bruce Mickey; Martha Stegner; Amyn A Habib; Karen Fink; Elizabeth A Maher; Robert M Bachoo
Journal:  J Neurooncol       Date:  2014-02-12       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.